glyxambi film-coated tablets 10 mg5 mg
boehringer ingelheim singapore pte. ltd. - empagliflozin; linagliptin - tablet, film coated - empagliflozin 10.00 mg; linagliptin 5.00 mg
glyxambi film-coated tablets 25 mg5 mg
boehringer ingelheim singapore pte. ltd. - empagliflozin; linagliptin - tablet, film coated - empagliflozin 25.00 mg; linagliptin 5.00 mg
jardiamet
boehringer ingelheim (nz) ltd - empagliflozin 12.5mg; ; metformin hydrochloride 1000mg; - film coated tablet - 12.5mg/1000mg - active: empagliflozin 12.5mg metformin hydrochloride 1000mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry purple 02b200006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) ltd - empagliflozin 12.5mg; ; metformin hydrochloride 500mg; - film coated tablet - 12.5mg/500mg - active: empagliflozin 12.5mg metformin hydrochloride 500mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b20004 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) ltd - empagliflozin 12.5mg; ; metformin hydrochloride 850mg; - film coated tablet - 12.5mg/850mg - active: empagliflozin 12.5mg metformin hydrochloride 850mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry pink 02b240006 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) ltd - empagliflozin 5mg; ; metformin hydrochloride 1000mg; - film coated tablet - 5mg/1000mg - active: empagliflozin 5mg metformin hydrochloride 1000mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220012 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) ltd - empagliflozin 5mg; ; metformin hydrochloride 500mg; - film coated tablet - 5mg/500mg - active: empagliflozin 5mg metformin hydrochloride 500mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220011 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) ltd - empagliflozin 5mg; ; metformin hydrochloride 850mg; - film coated tablet - 5mg/850mg - active: empagliflozin 5mg metformin hydrochloride 850mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220010 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
linagliptin pharos 5 mg film-coated tablets
pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - linagliptin 5 mg - drugs used in diabetes
synjardy
boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, type 2 - drugs used in diabetes - synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets.